The Efficacy of Ferumoxytol in Peritoneal Dialysis Patients: A Short Scientific Report

Sayed Husain, Hani Judeh, Manaf Alroumoh, Farhana Yousaf, Prince Mohan, Ahla Husain, Chaim Charytan, Bruce Spinowitz

Cape Fear Valley Hospital NC, Fayetteville, USA.
Columbia Medical University, New York, USA.
New York Hospital Queens, New York, USA.
South Texas Regional Medical Center, San Antonio, USA.
St. Luks/Roosevelet Hospital, New York, USA.

DOI: 10.4236/ojneph.2014.42014                

Abstract

One of the major elements contributing to anemia in Chronic Kidney Disease (CKD) patients is iron deficiency. Iron supplementation in oral form is often not tolerated and ineffectively absorbed. Intravenous (IV) infusion is time consuming and is inconvenient in Peritoneal Dialysis (PD) patients self-treating at home. A new preparation of iron, ferumoxytol, is a carbohydrate-coated, paramagnetic iron oxide nanoparticle, which can be administered as a bolus intravenous injection, allowing the PD patient to more easily comply with current IV iron dosing regimens. Few studies have been done to evaluate the efficacy of ferumoxytol in PD population. We retrospectively reviewed the medical records of peritoneal dialysis patients who received at least one dose of ferumoxytol between January 2010 and August 2010 and observed that 17 patients showed an improvement in hemoglobin (Hb) to 1 gm/dl within a month of treatment along with a decrease in epoetin dosage in subsequent weeks.

Keywords

Anemia, Ferumoxytol, Peritoneal Dialysis

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K. and Adamson, J.W. (1987) Correction of the Anemia of End-Stage Renal Disease with Crecombinant Human Erythropoietin: Results of a Combined Phase I and II Clinical Trial. New England Journal of Medicine, 316, 73-78. http://dx.doi.org/10.1056/NEJM198701083160203
[2]	Gotloib, L., Silverberg, D., Fudin, R. and Shostak, A. (2006) Iron Deficiency Is a Common Cause of Anemia in Chronic Kidney Disease and Can Often Be Corrected with Intravenous Iron. Journal of Nephrology, 19, 161.
[3]	AMAG Pharmaceuticals, Inc. (2009) Feraheme (Ferumoxytol) Package Insert. Lexington.
[4]	Balakrishnan, V.S., Rao, M., Kausz, A.T., et al. (2009) Physicochemical Properties of Ferumoxytol, a New Intravenous Iron Preparation. European Journal of Clinical Investment, 39, 489-496. http://dx.doi.org/10.1111/j.1365-2362.2009.02130.x
[5]	Iain, C.M., et al. (2014) A Randomized Comparison of Ferumoxytol and Iron Sucrose for Treating Iron Deficiency Anemia in Patients with CKD CJASN ePress. http://dx.doi.org/10.2215/CJN.05320513